Dataset from A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00009322
下载链接
链接失效反馈官方服务：
资源简介：
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth
factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non
Small Cell Lung Cancer
创建时间：
2026-03-02
